GlassScriptPhysician profile
David J Gorecki
NPI 1316923444
$3,747.40
in general payments reported to CMS, 2019-2025
24 companies · $33.36 in 2025
The $33.36 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $418 · 2021: $350 · 2022: $849 · 2023: $911 · 2024: $407 · 2025: $33.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,282.84 | 2019-2025 | |
| Amgen INC. | $534.78 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $428.43 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $226.55 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $184.75 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $163.80 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $132.69 | 2021-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $124.87 | 2019-2022 | |
| Abbott Laboratories | $124.80 | 2023-2024 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.74 | 2020-2023 | Jardiance |
| Esperion Therapeutics, INC. | $97.29 | 2021-2023 | Nexletol |
| Boston Scientific Corporation | $55.72 | 2022 | |
| Gilead Sciences, INC. | $47.03 | 2019 | |
| Scpharmaceuticals INC. | $41.37 | 2023-2024 | |
| Pfizer INC. | $39.97 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $25.75 | 2021 | |
| Cvrx, INC. | $25.32 | 2024 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $24.94 | 2022 | |
| Amryt Pharma Holdings LTD | $22.54 | 2023 | Juxtapid |
| Chiesi USA, INC. | $15.57 | 2019 | |
| Edwards Lifesciences Corporation | $14.05 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Vifor Pharma, INC. | $13.10 | 2020 | |
| Itamar Medical INC | $11.84 | 2023 | Watchpatone |
| Amarin Pharma, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gorecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.